After classical antibody inhibitors had failed to show an effect on muscle growth in Duchenne Muscular Dystrophy (DMD) [86], an Adnectin monobody targeting myostatin was fused with an IgG1-Fc domain to produce a clinical inhibitor [87]. Here, MSTN is linked to Duchenne muscular dystrophy.